Mirdametinib: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Mirdametinib. Educational only — not medical advice.
Labeled uses
GOMEKLI is indicated for the treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection [see Clinical Studies (14) ].
Source: FDA labeling via NIH DailyMed (set 4c41bf90…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.